|
| Status |
Public on Aug 14, 2022 |
| Title |
Impact of ALK inhibition or phospho-deficient mutation of CDK9 on gene expression in ovarian cancer cells |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
The goal of this study is to determine the impact of ALK inhibition or phospho-deficient mutation of CDK9 on gene expresion profiles in ovarian cancer cells
|
| |
|
| Overall design |
We performed bulk RNA sequencing on three cellular phenotypes: (1) cells expressing WT CDK9, (2) cells expressing WT CDK9 treated with an ALK inhibitor, and (3) cells expressing Y19F-mutant (phospho-deficient) CDK9
|
| |
|
| Contributor(s) |
Hung M, Chu Y |
| Citation(s) |
36253486 |
| |
| Submission date |
Nov 28, 2021 |
| Last update date |
Nov 02, 2022 |
| Contact name |
YU YI CHU |
| Organization name |
MD Anderson Cancer Center
|
| Department |
Molecular and Cellular Oncology
|
| Street address |
6565 MD Anderson Blvd
|
| City |
Houston |
| State/province |
Texas |
| ZIP/Postal code |
77030 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
|
| Samples (9)
|
|
| Relations |
| BioProject |
PRJNA784195 |
| SRA |
SRP348231 |
Less...
More...